Copenhagen and Oslo, 30th March 2012, 2012-03-30 14:06 CEST (GLOBE NEWSWIRE) -- Affitech A/S (NASDAQ OMX: AFFI) announces that Teknoinvest AS has sold 1,669,000 shares in Affitech A/S at a total value of DKK 333,800. After this sale, Teknoinvest AS has no shares in Affitech. Managing Director of Teknoinvest AS, Mr. Steven Morrell is a Board member of Affitech A/S.
Eiken Invest 2000 AS, a wholly owned subsidiary of Teknoinvest AS, has sold 234,484 shares in Affitech AS at a total value of DKK 46,896.80. After this sale Eiken Invest 2000 AS has no shares in Affitech A/S.
About Affitech
Affitech A/S is a publicly traded (NASDAQ OMX Copenhagen) human therapeutic antibody company based in Copenhagen, Denmark with R&D facilities in Oslo, Norway. The company utilizes a range of proprietary antibody technologies for the discovery of fully human antibodies for application in oncology, inflammation and other disease areas. CBAS™ (Cell Based Antibody Selection) is Affitech’s premier discovery engine for the isolation of lead antibodies to cell surface molecules in situ. Several of the Company's proprietary product candidates were generated by CBAS™. Further information is available at www.affitech.com.
For more information please contact
Randi Krogsgaard, Director IR & Communications
Tel # +45 2320 1001, e-mail: ir@affitech.com
